Purdue Pharma L.P.
Case Number:
7:19-bk-23649
Court:
Nature of Suit:
Firms
- Kobre & Kim
- Brown & Connery
- Willkie Farr
- Blitman & King
- Bielli & Klauder
- Tarter Krinsky
- Teitelbaum Law Group
- Cleary Gottlieb
- McDermott Will & Schulte
- Simmons Hanly
- Kirkland & Ellis
- Goodwin Procter
- Godfrey & Kahn
- Gilbert LLP
- Himes Petrarca
- Jones Day
- Morgan Lewis
- Wachtell Lipton
- Hurwitz Fine
- Skadden Arps
- Lowe Stein
- Pillsbury Winthrop
- Reed Smith
- Klehr Harrison
- Squire Patton
- Archer & Greiner
- Porter Hedges
- Gage Spencer & Fleming
- Pashman Stein
- Shook Hardy
- Taft Stettinius
- Brown Rudnick
- WilmerHale
- Faegre Drinker
- Blank Rome
- Hogan Lovells
- Gertz & Rosen
- Arnold & Porter
- Porteous Hainkel
- White & Case
- Andrews & Thornton
- Dentons
- Troutman
- Doster Ullom
- Bentley & Bruning
- ASK LLP
- BatesCarey
- Joseph Hage
- Phillips Lytle
- Spangenberg Shibley
- Cuneo Gilbert
- Debevoise & Plimpton
- Mintz Levin
- WestLoop Law
- Miller Nash LLP
- ArentFox Schiff
- McGrail & Bensinger
- Cronin Fried
- Loeb & Loeb
- Robins Kaplan
- MoloLamken
- Slevin & Hart
- Doshi Legal Group
- Schenck Price
- Lerner Arnold
- Bialson Bergen
- Martin S. Rapaport
- Marino Tortorella
- Motley Rice
- Saul Ewing
- Burke Warren
- Wilk Auslander
- Stutzman Bromberg
- Duane Morris
- Hagens Berman
- Consovoy McCarthy
- Napoli Shkolnik
- Marcus & Shapira
- Quinn Emanuel
- Pachulski Stang
- King & Spalding
- Potter Anderson
- Stevens & Lee
- Shafferman & Feldman
- Ballard Spahr
- Hughes Socol
- Foley & Lardner
- Seyfarth Shaw
- Keller Rohrback
- O'Melveny & Myers
- Davis Polk
- Keller Postman
- Kleinberg Kaplan
- Katsky Korins
- Clifford Law Offices
- Barack Ferrazzano
- Crowell & Moring
- Terrell Hogan
- Sherrard Roe
- Levenfeld Pearlstein
- Rothstein Mandell
- MacElree Harvey
- Pullman & Comley
- Mehri & Skalet
- Tate Law Group LLC
- Frost Brown
- Lowey Dannenberg
- Williams Mullen
- UB Greensfelder
- Waldrep Wall
- Dechert LLP
- Ifrah Law
- Seward & Kissel
- Simpson Thacher & Bartlett LLP
- Calfee Halter
- White Coleman & Associates
- Caplin & Drysdale
- Miller Shah
- O'Brien Belland
- Binder & Schwartz
- Alston & Bird
- Akin Gump
- Carter Ledyard
- Shipman & Goodwin
- McElroy Deutsch
- Henrichsen Law Group
- Jenner & Block
- Haug Partners
- HSF Kramer
- Hobbs Straus
- Latham & Watkins
- Mayer Brown
- Milbank LLP
Companies
- Teamsters Local 456
- Henry Schein Inc.
- Hikma Pharmaceuticals PLC
- McKesson Corp.
- Otis Worldwide Corp.
- Impax Laboratories, Inc.
- Kodiak Area Native Association
- Ranbaxy
- Tucson Medical Center
- PRA Health Sciences Inc.
- Ascent Pharmaceuticals Inc.
- Blue Cross Blue Shield Association
- Aleutian Pribilof Islands Association Inc.
- Collegium Pharmaceutical Inc.
- Endo International PLC
- Giant Eagle Inc.
- Omnicare Inc.
- Bausch Health Cos. Inc.
- Province LLC
- United Parcel Service Inc.
- Sandoz International GmbH
- Avrio Health LP
- Nardello & Co. LLC
- DuPont de Nemours Inc.
- Johnson & Johnson
- Hain Capital Group LLC
- Express Scripts Holding Co.
- CVS Health Corp.
- KVK Tech Inc.
- Amneal Pharmaceuticals Inc.
- Sun Pharmaceutical Industries Ltd.
- Loblaw Cos.
- TR Capital Management LLC
- The Cigna Group
- Cencora Inc.
- Ironshore Inc.
- Bristol-Myers Squibb Co.
- Viatris Inc.
- Noramco Inc.
- Alaska Native Tribal Health Consortium
- Walmart Inc.
- Anda Inc.
- AlixPartners LLP
- AXA XL Ltd.
- Allergan PLC
- FTI Consulting Inc.
- Purdue Pharma LP
- United Food & Commercial Workers International Union
- ASM Capital LP
- SAP AG
- Apria Healthcare Group
- Cardinal Health Inc.
- Liberty Mutual Insurance Group
- Arcadia Consumer Healthcare
- International Union Of Operating Engineers
- Old Republic Insurance Co.
- Oracle Corp.
- Thermo Fisher Scientific Inc.
- Verita Global LLC
- Houlihan Lokey Inc.
- American Federation of Labor & Congress of Industrial Organizations
- Jefferies Financial Group Inc.
- Teva Pharmaceutical Industries Ltd.
Government Agencies
- Seldovia Village Tribe
- State of Indiana
- Missouri Department of Revenue
- Tennessee Attorney General's Office
- Pala Band of Mission Indians
- Town of Ramapo, New York
- Pension Benefit Guaranty Corp.
- City of Bayonne, New Jersey
- Commonwealth of Massachusetts
- State of Nevada
- Washington State Department of Revenue
- Nez Perce Tribe
- Port Gamble S'Klallam Tribe
- U.S. District Court for the District of Columbia
- Borough of Paramus, New Jersey
- Jamestown S'Klallam Tribe
- Northwestern Band of the Shoshone Nation
- St. Regis Mohawk Tribe
- Town of Babylon, New York
- Town of Brookhaven, New York
- New York Department of Financial Services
- Town of Hempstead, New York
- Hopi Tribe
- Suquamish Tribe
- Ohio Attorney General's Office
Sectors & Industries:
-
November 18, 2025
Purdue's $7.4B Ch. 11 Plan Jibes With New Release Paradigm
A New York bankruptcy judge gave a bench ruling Tuesday explaining his decision to confirm Purdue's $7.4 billion Chapter 11 plan, which transforms the pharmaceutical giant into a public benefit company, ruling that liability releases fully comply with new restrictions imposed by the U.S. Supreme Court last year.
-
November 17, 2025
Purdue, Sunnova Score Approvals For Ch. 11 Plans
Purdue Pharma secured a judge's approval of its new bankruptcy plan. The U.S. Supreme Court won't review a ruling regarding the Serta Simmons Chapter 11 plan. And solar panel company Sunnova also got a court's permission to implement a bankruptcy plan.
-
November 14, 2025
Purdue's $7.4B Ch. 11 Plan To Be Confirmed
A New York bankruptcy judge agreed to confirm the $7.4 billion Chapter 11 plan of Purdue Pharma LP on Friday, saying he would issue a formal bench ruling next Tuesday explaining his decision.
-
November 13, 2025
Objecting Claimants Have Their Say On Purdue Ch. 11 Plan
A New York bankruptcy judge heard statements from more than a dozen opioid personal injury claimants objecting to the Chapter 11 plan of OxyContin maker Purdue Pharma Thursday as the pro se objectors shared concerns about their recoveries, the lack of criminal prosecution of the company's owners and faults in the system that allowed the opioid crisis to occur in the first place.
-
November 12, 2025
Purdue Kicks Off Ch. 11 Confirmation With Plan Overview
Bankrupt OxyContin maker Purdue Pharma began its Chapter 11 confirmation trial Wednesday with an overview of its latest plan and the myriad settlements that underpin the proposal, including a $6.5 billion commitment from the company's owners.
-
November 07, 2025
Purdue Expects Smooth Confirmation Of New $7.5B Plan
Bankrupt drugmaker Purdue Pharma will begin a confirmation trial for its latest Chapter 11 plan Wednesday in a vastly different position than the last time it came to court seeking similar relief in 2021, when a New York judge approved a plan — over the objections of key parties — that was later struck down by the U.S. Supreme Court.
-
November 07, 2025
What's Happening In Bankruptcy Court This Coming Week
It's a confirmation-seeking bonanza in the coming week as the Archdiocese of New Orleans will come to court for a pretrial conference related to its bankruptcy plan, Purdue will seek confirmation of its Chapter 11 plan, and Yellow Corp. will make its own bid for plan approval.
-
October 27, 2025
Purdue Defends Ch. 11 Plan, Heritage Coal's Gets OK'd
Pharmaceutical titan Purdue Pharma hailed support for its proposed bankruptcy plan and fought an objection from the city of Baltimore, Heritage Coal got its Chapter 11 plan approved, and a Texas bankruptcy judge granted LifeScan's conditional approval. This is the week in bankruptcy.
-
October 22, 2025
Purdue Fights Baltimore Objection Ahead Of Ch. 11 Plan Trial
Purdue Pharma LP told a New York bankruptcy judge on Wednesday it is concerned a recent objection to its Chapter 11 plan brought by the city of Baltimore could disrupt its case just weeks before the drugmaker is set to begin trial on a deal that creditors overwhelmingly support.
-
October 21, 2025
Purdue Touts Wide Support For Latest Ch. 11 Plan
Pharmaceutical titan Purdue Pharma heralded Tuesday that its newest Chapter 11 plan has almost total support from voting creditors, saying the proposal could pave the way to creditors receiving more than $7 billion, after its well-publicized role in the opioid epidemic pushed the company into bankruptcy and the U.S. Supreme Court rejected its original plan.